Welcome to our dedicated page for XWELL SEC filings (Ticker: XWEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XWELL, Inc. (Nasdaq: XWEL) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about XWELL’s capital structure, governance, stockholder actions, and financial reporting as a global wellness holding company with brands such as XpresSpa, Naples Wax Center, XpresCheck, and HyperPointe.
Through its current reports on Form 8-K, XWELL discloses material events including notices from The Nasdaq Stock Market regarding minimum bid price compliance, actions taken to regain or maintain compliance, and updates on annual meeting scheduling and outcomes. Other 8-K filings describe entry into material definitive agreements, such as transactions involving Series G Convertible Preferred Stock, amended and restated warrants, and senior secured convertible notes, along with related amendments to the company’s certificate of designations and capital structure.
XWELL’s definitive proxy statements on Schedule 14A provide insight into corporate governance matters. These filings outline proposals presented to stockholders, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation and its frequency, potential board classification, reverse stock split proposals, and adjournment proposals. The proxy materials also explain record dates, virtual meeting procedures, and voting requirements.
Investors can use this page to locate annual meeting results reported on Form 8-K, which summarize how stockholders voted on director elections, auditor ratification, compensation advisory votes, capital structure changes, and share issuance approvals under Nasdaq Listing Rule 5635. Filings also document the company’s responses to Nasdaq listing notices and the status of its listing on The Nasdaq Capital Market.
Stock Titan’s platform supplements these filings with AI-powered tools that help interpret complex documents such as 8-Ks and proxy statements. While the underlying filings remain the authoritative source, AI-generated summaries can highlight key terms of financing arrangements, reverse stock split approvals, and governance changes, making it easier to understand how XWELL’s regulatory disclosures relate to its wellness, biosecurity, and capital markets strategies.
XWELL, Inc. (Nasdaq: XWEL) has filed Amendment No. 3 to its Form S-3 shelf, registering 30,440,060 common shares for resale by prior investors.
The shares relate to a January 14 2025 private placement comprising: (i) 4,000 Series G convertible preferred shares translating into 23,952,096 conversion shares at a floor price of $0.167; (ii) 5,347,594 shares underlying cash-exercise warrants (Series A at $1.496, Series B at $1.7952); and (iii) up to 1,140,370 dividend shares accruing at 8 % per annum, compounded quarterly, through July 2030.
The registered amount equals roughly 557 % of the company’s outstanding common stock as of June 18 2025, signalling the potential for substantial dilution if all securities are issued. Proceeds from any resale go to the selling stockholders; XWELL would receive funds only if warrants are exercised for cash, earmarked for general corporate purposes. No underwriter is engaged, and sales may occur on Nasdaq or in private transactions.
XWELL is a non-accelerated, smaller-reporting company. Its shares last traded at $0.9039 on June 18 2025.